Background Assessment of clinical outcomes in the real-world corroborates findings from
randomized controlled trials (RCTs). Objective This meta-analysis evaluated real-world data …

Background After the approval of omalizumab for severe allergic asthma, a total of 25
studies have evaluated the effectiveness of omalizumab under “real-life” conditions of …

Introduction: Omalizumab is a recombinant monoclonal anti-IgE antibody approved in the
US as add-on treatment in moderate-to-severe allergic asthma (in severe allergic asthma …

Abstract We reviewed 24 'real‐life'effectiveness studies of omalizumab in the treatment of
severe allergic asthma that included 4117 unique patients from 32 countries with significant …

Abstract Background Omalizumab (anti-IgE monoclonal antibody) is an approved add-on
therapy for Japanese patients with severe allergic asthma. As directed by the Ministry of …

Abstract Background and Aims: Although the efficacy and safety of omalizumab (OMA) in
uncontrolled severe allergic asthma has been demonstrated in several randomised …

Omalizumab has demonstrated therapeutic benefits in controlled clinical trials. Evaluation of
outcomes in real-world clinical practice is needed to provide a complete understanding of …

Background: Inhaled corticosteroids (ICS) and long-acting β2-agonists (LABAs) are
recommended in patients with asthma that is not well-controlled; however, many patients …

Omalizumab has been shown to be an effective add-on therapy for patients with
uncontrolled severe persistent allergic asthma. There has been a steady accumulation of …

BACKGROUND: Omalizumab is a monoclonal antibody indicated for treatment of severe
persistent allergic asthma inadequately controlled despite optimal controller therapy. We …